---
title: Improve walking and movement control
nct_id: NCT07309198
phase: NA
status: RECRUITING
sponsor: Shanghai University of Sport
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07309198"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07309198"
last_fetched: "2026-05-10T14:03:51.216Z"
source: "Parkinson's Pathways (curated)"
---
# Improve walking and movement control

**Goal (in five words):** Improve walking and movement control

**Official Title:** Effects and Mechanisms of Non-invasive Deep Brain Stimulation in Patients With Parkinson's Disease

**Trial ID:** [NCT07309198](https://clinicaltrials.gov/study/NCT07309198)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Shanghai University of Sport
- **Target Enrollment:** 36 participants
- **Start Date:** 2025-12-29
- **Completion Date:** 2026-04-01
- **Conditions:** Parkinson's Disease
- **Interventions:** Transcranial Temporal Interference Stimulation (TIS)
- **Intervention Types:** DEVICE

## Summary For Families

They want to see whether noninvasive deep brain stimulation can change the deep motor circuits that drive Parkinson's movement problems and to learn how those changes happen. The method, transcranial temporal interference stimulation, sends two high-frequency electric fields that overlap to produce a low-frequency signal deep in the brain, modulating activity in targets like the basal ganglia without directly stimulating the scalp, and it is tested while participants keep their usual Parkinsons meds unchanged. Looking for people aged 50 to 80 with physician-diagnosed idiopathic Parkinsons, Hoehn and Yahr stages 1.5 to 3 who can walk unassisted, on a stable antiparkinsonian regimen for at least 4 weeks, and with MoCA of 21 or higher. People with MRI or stimulation contraindications, prior DBS, current antipsychotic or antidepressant use, major psychiatric illness, certain cardiovascular or orthopedic risks are excluded.

## Eligibility

- **Minimum age:** 50 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* A physician-diagnosed idiopathic Parkinson's disease (PD) according to the Movement Disorder Society (MDS) diagnostic criteria, with onset after the age of 40.
* Stable antiparkinsonian medication regimen, including levodopa-containing therapy, unchanged for at least 4 weeks before and during the trial.
* Hoehn and Yahr (H\&Y) stages 1.5 to 3 and ability to walk unassisted.
* Absence of dementia, defined as a Montreal Cognitive Assessment (MoCA) score ≥ 21.

Exclusion Criteria:

* Any contraindication for MRI or transcranial temporal interference stimulation (TIS), including claustrophobia, metallic implants in the head or heart, or a history of electroconvulsive therapy.
* Current use of antipsychotic, antidepressant, or other dopamine-modulating medications.
* Presence of orthopedic conditions that may interfere with motor assessments, such as osteoarthritis or recent orthopedic surgery (within the past 6 months).
* History of physician-diagnosed major psychiatric illness.
* Physician-diagnosed cardiovascular risks that could contraindicate exercise or study participation.
* Prior history of deep brain stimulation (DBS) surgery.
```

## Locations (1)

- Shanghai University of Sport, Shanghai, Shanghai Municipality, China _(31.2222, 121.4581)_
  - Ethics Committee of the Shanghai University of Sport — (CONTACT) — +86 21 65508179 — lunli@sus.edu.cn

## Central Contacts

- Yu Liu, PhD — (CONTACT) — +86 21 65507351 — yuliu@sus.edu.cn

---

*Canonical: https://parkinsonspathways.com/trial/NCT07309198*  
*HTML version: https://parkinsonspathways.com/trial/NCT07309198*  
*Source data: https://clinicaltrials.gov/study/NCT07309198*